In the first conversation of our review of #TLM2024, panelists share general impressions and discuss the ESSENCE trial, semaglutide’s Phase 3 trial demonstrating regression of fibrosis.
Maru Rinella, corresponding author for the recent expert panel recommendations on resmetirom, joins the Surfers to discuss key points of the recommendations and the rationale behind them.
S5 E23 panelists Mike Betel and José WIllemse join Roger Green to review the three answers audience members sent for Season 5 Episode 23’s Question of the Week on Provider-Patient Communication.
In the second half of Roger Green’s interview with Global Liver Institute Vice President, Liver Programs Jeff McIntyre, Jeff discusses the implications of his key EASL Congress takeaways for GLI and other patient advocacy groups.
Global Liver Institute Vice President of Liver Programs Jeff McIntyre joins Roger Green to discuss what he considers key takeaways for GLI from EASL Congress 2024.
PharmaNest Founder and CEO Mathieu Petitjean joins Roger Green to discuss key implications for his business from what he learned at EASL Congress 2024.
PharmaNest Founder and CEO Mathieu Petitjean joins Roger Green to discuss key takeaways for his business from EASL Congress 2024.
PharmaNest Founder and CEO Mathieu Petitjean and Global LIver Institute Vice President of Liver Programs Jeff McIntyre join Roger Green for 1:1 interviews exploring their key takeaways and strategic shifts resulting from the EASL Congress 2024, followed by a review of answers to a previous Question of the Week.
Roger Green speaks with SurfingMASH co-host and Tawazun Health Founder and Clinical Director Louise Campbell on the last day of the EASL Congress. Their conversation focuses on how practice patterns, guidelines and training might change over the next few years.
Roger Green speaks with Hepatology Key Opinion Leader and EASL Educational Councillor Sven Francque 90 minutes after the EASL Congress closed. The discussion covers Clinical Practice Guidelines, drug development and NITs.
